tide mixed with 100 µL of H2O-TFA (triuoroacetic acid)
were injected into the column. Absorbance was monitored
at 220 and 280 nm. e peptides were ensured for non con-
tamination with endotoxin by Limulus Amebocyte Lysate
(1987 US FDA LAL test).
Bacteria were cultivated in Luria-Bertani standard liq-
uid medium during 2-3h at 37oС, 250 rpm. Logarithmic
phase cultures of bacteria were diluted in LB to an A630 =
0.01 (106 cfu/mL). Antimicrobial test was performed in 96-
well microtitration plates in a 100 µL nal volume using a
peptide concentration range from 200 to 1.5 µM according
the standards of CLSI (Clinical and Laboratory Standards
Institute, 2006). Each microtitration plate included positive
(0.7% formaldehyde solution) and negative control (H2O)
as well as sterility control (LB without bacteria). Each well
contained 50 µL of the microorganism suspension (106 cfu/
mL) and 50 µL of peptide solution or positive/negative con-
trol.
e content of antimicrobial microtitration plate is pre-
sented in Fig.1. Microtitration plate was aerward covered
with the lm, shortly incubated at 4°C during 1-2 hours and
rested overnight at 37°C, 150 rpm. e minimal inhibitory
concentrations (MICs) of Galarmin and analogues were
determined by measuring the absorbance (optical density -
OD) of the plate’s wells at 630 nm by plate automatic reader
(Asys UVM 340). e meaning of OD less than 0.2 shows
the absence/inhibition of bacterial growth, and 0.3 and
more, bacterial presence which correlate with the number
of OD. MIC was expressed as the lowest concentration of
peptide that completely inhibited bacterial growth.
Each experiment was performed in triplicate and al-
lowed to test the inhibitory activity of two peptides on one
bacterial strain. Statistical analysis of all data was performed
by Student-Fisher’s method of distribution with determina-
tion of t-criteria.
Beside the antimicrobial activity of peptides alone,
Galarmin and analogues (100 µM) were incubated with
bacteria in combination with secretory leucocyte protease
inhibitor (SLPI), another peptide known for its antimicro-
bial activity in vivo and in vitro. Human alarm antiprotease
SLPI is an 11.7 kDa cationic non-glycosylated protein con-
taining 107 amino acids that plays multiple important roles
in normal homoeostasis and inammation, including anti-
protease and antimicrobial activity 13. Recombinant SLPI
was provided by Prof. Jean-Michel Sallenave (Unit of Innate
Host Defence and Inammation, Institut Pasteur Paris).
RESULTS
e analysis of PRP by reverse-phase HPLC revealed
the purity and non contamination of all analyzed peptides
samples (Fig.2). Using the Limulus amebocyte lysate, we
showed that the preparation of PRP-1 was free of any endo-
toxin contamination.
e results of antimicrobial tests (OD of bacterial
growth) for Galarmin, Gx-NH2, d-15 Galarmin and dGx-
NH2 are represented at Table 1. On Table 2 are represented
the results of the eect of Galarmin and analogues on SLPI
(secretory leucocyte protease inhibitor) antimicrobial activ-
ity. e summarized results of antimicrobial tests are shown
on Tables 3 and 4.
DISCUSSION
As it is shown from the tables no direct inhibitory eect
was observed for Galarmin and analogues on MRSA and
other Gram-positive and Gram-negative bacterial strains.
No synergistic or inhibitory eects were observed for
Galarmin and analogues at concentration 100 µM when
these peptides were incubated in combination with SLPI at
a concentration producing (10 µM) or not (5 µM) growth-
inhibitory activity. Indeed, A630 values were approximately
the same for SLPI alone or in the presence of Galarmin and
analogues.
ese results clearly indicate that Galarmin and ana-
logues are devoid of antimicrobial properties and that the
strong protective eects observed in vivo against MRSA and
other pathogens are due to their immunomodulatory activi-
ties on host organisms.
ORIGINALNI RAD / ORIGINAL ARTICLE
strana / page 133
Comments to this Manuals